← Human Trials & Peer-Reviewed Studies
Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies
Plain-language guide to NCT06622187: phase 4 randomized trial of Desmopressin, 96 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06622187
- Phase
- phase 4
- Status
- enrolling by invitation
- Start
- 2024-08-14
- Completion (planned or actual)
- 2026-06
- Participants
- 96 (estimated)
- Design
- randomized, quadruple-blind, treatment
- Conditions studied
- Bleeding; Transplant, Kidney; Desmopressin; Kidney Biopsy
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (phase 4) is built around Desmopressin.
It had two arms (groups): Sodium Chloride (placebo comparator) and Desmopressin (DDAVP) (experimental).
The registry classes the interventions as drug.
Who Took Part
The registry lists 96 planned participants were the target.
It was open to people of any sex aged from 18 years with no upper age limit.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Need for graft biopsy as indicated by the kidney transplant medical team. Platelets \>80.000 cells/mm³. Blood pressure levels controlled before the procedure. Normal coagulogram levels.
The full record lists 5 inclusion and 4 exclusion criteria; among the exclusions: pregnant women; prior history of allergic reaction to ddavp; history of previous blood dyscrasias.
How the Study Was Run
The set-up was randomized, parallel-group and quadruple-blind.
The participants were allocated by chance, so the Desmopressin group and the comparison group should start out alike.
The Desmopressin group and the comparison group ran side by side rather than switching.
Neither the participants nor the staff measuring them knew who was on Desmopressin, so expectations could not easily colour the readings.
Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.
It started in 2024-08-14 with completion listed for 2026-06.
It ran at 1 site in Brazil.
Its stated primary purpose is treatment.
What Was Measured
The main thing measured (primary outcome): Bleeding events (time frame: Immediately post-biopsy until 48 hours post-biopsy).
It also tracked 2 secondary outcomes, for example Major bleeding and Minor bleeding.
What This Means in Plain Language
Put simply, this is a phase 4, randomized trial of Desmopressin in 96 people.
Its status is enrolling by invitation; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Desmopressin compound page, all human trials.
Our Notes on the Compound
Desmopressin: A synthetic vasopressin analog (DDAVP) used for bedwetting, diabetes insipidus and some bleeding disorders.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.